[go: up one dir, main page]

MA31744B1 - Compositions pharmaceutiques lyophilisees - Google Patents

Compositions pharmaceutiques lyophilisees

Info

Publication number
MA31744B1
MA31744B1 MA32691A MA32691A MA31744B1 MA 31744 B1 MA31744 B1 MA 31744B1 MA 32691 A MA32691 A MA 32691A MA 32691 A MA32691 A MA 32691A MA 31744 B1 MA31744 B1 MA 31744B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
orally
lyophilized pharmaceutical
administered parenterally
buffer
Prior art date
Application number
MA32691A
Other languages
Arabic (ar)
English (en)
Inventor
Thitiwan Buranachokpaisan
Wenlei Jiang
Wei-Qin Tong
Joseph Lawrence Zielinski
Jiahao Zhu
Hans-Peter Zobel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40005335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31744(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31744B1 publication Critical patent/MA31744B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur des compositions pharmaceutiques qui comprennent un composé thérapeutique peu soluble dans l'eau, un solvant aqueux, un chélateur/antioxydant, un tampon ou composant de tampon et un agent diluant. Les compositions pharmaceutiques peuvent être ingérées par voie orale ou administrées par voie parentérale. Les compositions pharmaceutiques peuvent en outre être lyophilisées pour former un agglomérat pharmaceutiquement acceptable, lequel pourra être administré par voie orale, par exemple en tant que forme posologique orale solide ; ou bien reconstitué et administré par voie parentérale, par exemple sous forme de bolus intraveineux ou de perfusion intraveineuse unique, ou par voie orale, par exemple sous forme de solution buvable.
MA32691A 2007-09-20 2010-03-12 Compositions pharmaceutiques lyophilisees MA31744B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97383007P 2007-09-20 2007-09-20
PCT/US2008/076752 WO2009039226A1 (fr) 2007-09-20 2008-09-18 Compositions pharmaceutiques lyophilisées

Publications (1)

Publication Number Publication Date
MA31744B1 true MA31744B1 (fr) 2010-10-01

Family

ID=40005335

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32691A MA31744B1 (fr) 2007-09-20 2010-03-12 Compositions pharmaceutiques lyophilisees

Country Status (20)

Country Link
US (1) US20100331387A1 (fr)
EP (1) EP2205222A1 (fr)
JP (1) JP2010540445A (fr)
KR (1) KR20100059887A (fr)
CN (1) CN101801345A (fr)
AR (1) AR068822A1 (fr)
AU (1) AU2008302273A1 (fr)
BR (1) BRPI0817118A2 (fr)
CA (1) CA2696914A1 (fr)
CL (1) CL2008002786A1 (fr)
CO (1) CO6270207A2 (fr)
EC (1) ECSP10010039A (fr)
GT (1) GT201000062A (fr)
MA (1) MA31744B1 (fr)
MX (1) MX2010002970A (fr)
PE (1) PE20090706A1 (fr)
RU (1) RU2010115262A (fr)
TN (1) TN2010000097A1 (fr)
TW (1) TW200930416A (fr)
WO (1) WO2009039226A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017242544B2 (en) * 2016-03-31 2022-11-24 Midatech Ltd. Cyclodextrin-panobinostat adduct

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR101139557B1 (ko) * 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아
JP2007501775A (ja) * 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
US20060128660A1 (en) * 2004-12-10 2006-06-15 Wisconsin Alumni Research Foundation FK228 analogs and methods of making and using the same
US7604939B2 (en) * 2005-03-01 2009-10-20 The Regents Of The University Of Michigan Methods of identifying active BRM expression-promoting HDAC inhibitors
AU2008204928B2 (en) * 2007-01-10 2011-03-31 Novartis Ag Formulations of deacetylase inhibitors
EP2120900A2 (fr) * 2007-02-15 2009-11-25 Novartis AG Combinaisons d'agents thérapeutiques pour le traitement du cancer

Also Published As

Publication number Publication date
ECSP10010039A (es) 2010-04-30
GT201000062A (es) 2012-03-30
CA2696914A1 (fr) 2009-03-26
RU2010115262A (ru) 2011-10-27
PE20090706A1 (es) 2009-07-15
AR068822A1 (es) 2009-12-09
TW200930416A (en) 2009-07-16
TN2010000097A1 (en) 2011-09-26
CO6270207A2 (es) 2011-04-20
US20100331387A1 (en) 2010-12-30
WO2009039226A1 (fr) 2009-03-26
MX2010002970A (es) 2010-04-01
CN101801345A (zh) 2010-08-11
JP2010540445A (ja) 2010-12-24
AU2008302273A1 (en) 2009-03-26
KR20100059887A (ko) 2010-06-04
CL2008002786A1 (es) 2009-05-15
BRPI0817118A2 (pt) 2019-09-24
EP2205222A1 (fr) 2010-07-14

Similar Documents

Publication Publication Date Title
MA27710A1 (fr) Formulations pharmaceutiques liquides de palonosetrone
CA3112680C (fr) Compositions comprenant un sulforaphane ou un precurseur de sulforaphane et un extrait ou une poudre de chardon marie
MA38576A1 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
MA29681B1 (fr) Formes galeniques du risedronate
MA32027B1 (fr) Preparation de capsules
MA31663B1 (fr) Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe
MA29744B1 (fr) Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree
WO2006108405A3 (fr) Conjugues de nanoparticules et d'agents actifs
MA34296B1 (fr) Composition retard injectable antipsychotique
MA33356B1 (fr) Compose anticancereux et composition pharmaceutique le contenant
MA28748B1 (fr) Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques
WO2007002181A3 (fr) Derives tetrahydrocarbazole convenant comme modulateurs du recepteur d'angrogene
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
NO20076595L (no) Behandling av leversykdommer hvor jern spiller en rolle i patogenesen
CO6260019A2 (es) Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento
MA34553B1 (fr) Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué
MA32275B1 (fr) Preparations orales et injectables de composes de tetracycline
ZA200800180B (en) Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative
WO2001047913A3 (fr) Derives substitues d'acide n-benzyl-indol-3-yl-glyoxalique a action antitumorale
Balakumar et al. A unifying perspective in blunting the limited oral bioavailability of curcumin: A succinct look
MA33602B1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide
AR046410A1 (es) Composiciones farmaceuticas para la liberacion modificada de modafinilo
MA29333B1 (fr) Preparations pharmaceutiques d'aerosol pour aerosols-doseurs pressurises contenant un agent sequestrant
MA31744B1 (fr) Compositions pharmaceutiques lyophilisees
CO2021005221A2 (es) Formulación basada en ciclodextrina de un inhibidor de bcl-2